New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis

The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) has reinforced the need for the development of new anti-TB drugs. The first line drug isoniazid inhibits InhA. This is a prodrug requiring activation by the enzyme KatG. Mutations in KatG have largely c...

Descripción completa

Detalles Bibliográficos
Autores principales: Chetty, Sarentha, Armstrong, Tom, Sharma Kharkwal, Shalu, Drewe, William C., De Matteis, Cristina I., Evangelopoulos, Dimitrios, Bhakta, Sanjib, Thomas, Neil R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070701/
https://www.ncbi.nlm.nih.gov/pubmed/33919737
http://dx.doi.org/10.3390/ph14040361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070701/
https://www.ncbi.nlm.nih.gov/pubmed/33919737
http://dx.doi.org/10.3390/ph14040361

Ejemplares similares